Nuhad K. Ibrahim

14.6k total citations · 5 hit papers
145 papers, 10.0k citations indexed

About

Nuhad K. Ibrahim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Nuhad K. Ibrahim has authored 145 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 40 papers in Cancer Research. Recurrent topics in Nuhad K. Ibrahim's work include Cancer Treatment and Pharmacology (49 papers), HER2/EGFR in Cancer Research (36 papers) and Breast Cancer Treatment Studies (33 papers). Nuhad K. Ibrahim is often cited by papers focused on Cancer Treatment and Pharmacology (49 papers), HER2/EGFR in Cancer Research (36 papers) and Breast Cancer Treatment Studies (33 papers). Nuhad K. Ibrahim collaborates with scholars based in United States, United Kingdom and France. Nuhad K. Ibrahim's co-authors include Gabriel N. Hortobágyi, Lajos Pusztai, Richard L. Theriault, W. Fraser Symmans, Kenneth R. Hess, Aman U. Buzdar, Vicente Valero, Daniel J. Booser, Massimo Cristofanilli and Roman Rouzier and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Nuhad K. Ibrahim

142 papers receiving 9.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

2005 1.4k citations Roman Rouzier, Charles M. Perou et al. Clinical Cancer Research profile →
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

2006 553 citations Kenneth R. Hess, K. Anderson et al. Journal of Clinical Oncology profile →
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

2002 504 citations Nuhad K. Ibrahim, Richard L. Theriault et al. profile →
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group

2020 468 citations Nuhad K. Ibrahim et al. The Oncologist profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nuhad K. Ibrahim United States	42	6.3k	3.9k	2.8k	1.8k	1.1k	145	10.0k
George Somlo United States	51	6.1k 1.0×	3.8k 1.0×	4.7k 1.7×	1.8k 1.0×	957 0.8×	279	12.2k
Christoph Thomssen Germany	53	4.9k 0.8×	4.5k 1.1×	2.2k 0.8×	1.2k 0.7×	810 0.7×	281	8.4k
Sheila E. Taube United States	21	4.5k 0.7×	3.5k 0.9×	3.2k 1.1×	1.8k 1.0×	893 0.8×	38	9.0k
Stefan Michiels France	53	6.9k 1.1×	3.8k 1.0×	3.7k 1.3×	2.9k 1.7×	911 0.8×	265	12.2k
Fabio Puglisi Italy	43	4.8k 0.8×	2.5k 0.6×	2.3k 0.8×	2.4k 1.3×	971 0.8×	359	8.3k
Alberto Ocaña Spain	51	7.3k 1.2×	2.5k 0.6×	3.8k 1.4×	2.5k 1.4×	1.7k 1.5×	302	12.3k
Herbert A. Fritsche United States	48	5.8k 0.9×	3.9k 1.0×	3.4k 1.2×	2.8k 1.6×	1.4k 1.2×	163	11.2k
Stephen Chan United Kingdom	47	7.5k 1.2×	2.7k 0.7×	3.8k 1.4×	2.6k 1.4×	1.8k 1.6×	194	11.2k
Henry Gómez Peru	46	5.3k 0.8×	2.6k 0.7×	2.6k 0.9×	1.8k 1.0×	801 0.7×	205	8.3k
P. Fumoleau France	61	9.6k 1.5×	4.4k 1.1×	3.3k 1.2×	2.7k 1.5×	2.3k 2.0×	326	14.3k

Countries citing papers authored by Nuhad K. Ibrahim

Since Specialization

Citations

This map shows the geographic impact of Nuhad K. Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nuhad K. Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nuhad K. Ibrahim more than expected).

Fields of papers citing papers by Nuhad K. Ibrahim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nuhad K. Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nuhad K. Ibrahim. The network helps show where Nuhad K. Ibrahim may publish in the future.

Co-authorship network of co-authors of Nuhad K. Ibrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Nuhad K. Ibrahim. A scholar is included among the top collaborators of Nuhad K. Ibrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nuhad K. Ibrahim. Nuhad K. Ibrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ibrahim, Nuhad K., Sung‐Bae Kim, Nancy U. Lin, et al.. (2024). Abstract PO2-05-05: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC). Cancer Research. 84(9_Supplement). PO2–5. 3 indexed citations

Bond, Katherine, Claire Dendle, Monica A. Slavin, et al.. (2024). Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series. Open Forum Infectious Diseases. 11(8). ofae449–ofae449. 1 indexed citations

Forget, Frédéric, Serafín Morales, Nuhad K. Ibrahim, et al.. (2024). AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.. Journal of Clinical Oncology. 42(16_suppl). TPS1125–TPS1125. 1 indexed citations

Raghavendra, Akshara Singareeka & Nuhad K. Ibrahim. (2024). Breast Cancer Brain Metastasis: A Comprehensive Review. JCO Oncology Practice. 20(10). 1348–1359. 19 indexed citations

Damodaran, Senthil, Diane Liu, Jill L. Schwartz, et al.. (2023). Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). Cancer Research. 83(5_Supplement). P3–2. 2 indexed citations

Garber, Haven R., Akshara Singareeka Raghavendra, Wei Qiao, et al.. (2022). Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. npj Breast Cancer. 8(1). 46–46. 18 indexed citations

Lin, Nancy U., Mark D. Pegram, Solmaz Sahebjam, et al.. (2021). Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology. 39(24). 2667–2675. 67 indexed citations

Alhalabi, Omar, Ryan Sun, Elshad Hasanov, et al.. (2021). Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. npj Breast Cancer. 7(1). 28–28. 5 indexed citations

Kumthekar, Priya, Shou‐Ching Tang, Andrew Brenner, et al.. (2020). ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research. 26(12). 2789–2799. 178 indexed citations

10.

Farsaci, Benedetto, Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research. 4(9). 755–765. 26 indexed citations

11.

Kumthekar, Priya, Shou‐Ching Tang, Andrew Brenner, et al.. (2016). OS7.2 A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer. Neuro-Oncology. 18(suppl_4). iv16–iv16. 7 indexed citations

12.

Moulder, Stacy L., Jennifer K. Litton, EA Mittendorf, et al.. (2016). Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease. Annals of Oncology. 27. vi67–vi67. 1 indexed citations

13.

Shen, Qi, Ayşegül A. Şahin, Kenneth R. Hess, et al.. (2015). Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis. The Oncologist. 20(5). 466–473. 62 indexed citations

14.

Finn, Richard S., Carmelo Bengala, Nuhad K. Ibrahim, et al.. (2011). Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clinical Cancer Research. 17(21). 6905–6913. 187 indexed citations

15.

Tabchy, Adel, Vicente Valero, Tatiana Vidaurre, et al.. (2010). Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research. 16(21). 5351–5361. 160 indexed citations

16.

Royer, Bernard, et al.. (2010). Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. British Journal of Cancer. 102(5). 827–832. 11 indexed citations

17.

Buzdar, Aman U., Vicente Valero, Nuhad K. Ibrahim, et al.. (2007). Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research. 13(1). 228–233. 346 indexed citations

18.

Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685. 867 indexed citations breakdown →

19.

Rouzier, Roman, Charles M. Perou, W. Fraser Symmans, et al.. (2005). Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research. 11(16). 5678–5685. 1414 indexed citations breakdown →

20.

Symmans, W. Fraser, Mark Ayers, Edwin Clark, et al.. (2003). Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma. Cancer. 97(12). 2960–2971. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact